FDA
-
-
-
-
-
-
-
BridgeBio raises $1 billion in convertible preferred equity
-
-
-
-
-
-
-
BridgeBio Announces FDA Acceptance and Priority Review of NDA for BBP-418 for LGMD2I/R9
-
-
-
-
-
-
-
BEYONTTRA™ (acoramidis), the First Near-Complete TTR Stabilizer (≥90%), Approved by ANVISA to Treat ATTR-CM in Brazil
-
-
-
-
-
-
-
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
-
-
-
-
-
-
-
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
-
-
-
-
-
-
-
BridgeBio Pharma (BBIO) PT Raised to $75 at Leerink Partners
-
-
-
-
-
-
-
Piper Sandler: 'Biotech Has a Heartbeat: 17 Stocks to Own Through YE25'
-
328,268 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

